

# AGENDA

**Translational Advances in Cancer Prevention Agent Development**  
*Sponsored by the Division of Cancer Prevention, National Cancer Institute  
and the Office of Disease Prevention*

**DATE: August 27-28, 2020**

**Day 1 Morning Session (9:00 to 11:30 AM)**

9:00-9:30 AM

**Welcome Remarks**

Philip Castle, Ph.D., M.P.H., Director, Division of Cancer Prevention, NCI

Mark Miller, Ph.D., Program Director, Division of Cancer Prevention, NCI

**Session I\***

**Advances in Small Molecule Agent Development**

*Co-Chairs: Margie Clapper, Ph.D. and Thomas Kensler, Ph.D.*

9:30-10:00 AM

Speaker 1: Margie Clapper, Ph.D., Fox Chase Cancer Center

*Estrogen metabolism: A target for intervention in non-small cell lung cancer*

10:00-10:30 AM

Speaker 2: Karen Liby, Ph.D., Michigan State University

*Targeting the immune system for the prevention of Kras-driven cancers*

10:30-11:00 AM

Speaker 3: Zelton (Dave) Sharp, Ph.D., University of Texas at San Antonio

*Cancer and aging prevention by mTOR inhibition*

11:00-11:30 AM

Speaker 4: Thomas Kensler, Ph.D., Fred Hutchinson Cancer Research Center

*Bringing broccoli sprouts (Sulforaphane) to clinical trials: dose matters*

**11:30-12:15 PM**

**Break**

**Day 1 Early Afternoon Session (12:15 to 3:15 PM)**

12:15-1:15 AM

**Translational Research Plenary Speaker**

Raymond DuBois, M.D., Ph.D., Medical University of South Carolina

*Inflammation and inflammatory mediators as targets for cancer prevention/interception*

**\*Session talks will be 20 min with 10 min Q&A**

## Session II

### **Advances in Immunomodulatory Agent Development**

*Co-chairs: Jill Siegfried, Ph.D. and Robert H. Shoemaker, Ph.D.*

- 1:15-1:45 PM Speaker 1: Jill Siegfried, Ph.D., University of Minnesota  
*A STAT3 decoy for lung cancer prevention*
- 1:45-2:15 PM Speaker 2: Robert Glynn, Sc.D., Harvard Medical School  
*Mediation analysis to elucidate the role of inflammation reduction in cancer prevention: exploratory findings from the CANTOS trial*
- 2:15-2:45 PM Speaker 3: Haval Shirwan, Ph.D., University of Missouri, Columbia  
*CD137 immune checkpoint pathway as an effective target for cancer immunoprevention*
- 2:45-3:15 PM Speaker 4: Shadmehr Demehri, M.D., Ph.D., Massachusetts General Hospital  
*Epithelium-derived alarmins role in breast cancer immunoprevention*
- 3:15 – 4:00 PM **Break**

## Day 1 Late Afternoon Session (4:00 to 6:30 PM)

## Session III

### **Alternative Dosing and Combination Strategies to Reduce Toxicity**

*Co-Chairs: Ming You, M.D., Ph.D. and Altaf Mohammed, Ph.D.*

- 4:00-4:30 PM Speaker 1: Ming You, M.D., Ph.D., Wisconsin Medical Center  
*Chemoprevention with aerosolized let-7 micro-RNA in mouse models of lung cancer*
- 4:30- 5:00 PM Speaker 2: Susan Mallery, D.D.S., Ph.D., Ohio State University  
*Location, location, location: oral cancer chemoprevention by local delivery*
- 5:00-5:30 PM Speaker 3: C.V. Rao, Ph.D., University of Oklahoma  
*Safer chemopreventive approaches to colonic adenoma prevention*
- 5:30-6:00 PM Speaker 4: Emmanuelle Meuillet, Ph.D., PHusis Therapeutics  
*Preventing Skin cancer in high risk individuals with Actinic Keratosis using targeted AKT/PDK1 inhibitor, PHT-427*
- 6:00-6:30 PM Speaker 5: Roderick Dashwood, Ph.D., Texas A&M Health Science Center  
*Optimizing dosing regimens of Erlotinib and Sulindac in a preclinical model of FAP*

**Day 2 Morning Session (10:00 AM to 1:30 PM)**

10:00-10:15 AM      **Open Morning Session**

Altaf Mohammed, Ph.D., Division of Cancer Prevention, NCI

10:15-11:00 AM      **NCI PREVENT Preclinical Drug Development Program**

Mark Miller, Ph.D., Division of Cancer Prevention, NCI

**Session IV**

**Emerging Vaccines for Cancer Prevention**

*Co-Chairs: Steven Lipkin, M.D., Ph.D. and Shizuko Sei, M.D.*

11:00-11:30 AM      Speaker 1: Steven Lipkin, M.D., Ph.D. Weill Cornell University

*Immunoprevention for Lynch Syndrome*

11:30-12:00 PM      Speaker 2: Robert Schoen, M.D., M.P.H., University of Pittsburgh

*MUC1 vaccine for prevention of colorectal adenoma*

12:00-12:30 PM      Speaker 3: Richard Roden, Ph.D., Johns Hopkins University

*Development of vaccines for broad protection against and elimination of HPV infection*

12:30-1:00 PM      Speaker 4: Bryon Johnson, Ph.D., Wisconsin Medical Center

*Development of a Kras preventive vaccine*

1:00-1:30 PM      Speaker 5: Mary (Nora) Disis, M.D., University of Washington

*Vaccines targeting cancer initiation associated proteins*

**1:30 -2:30 PM Break**

**Day 2 Afternoon Session (2:30 to 6:15 PM)**

2:30-3:30 PM      **Clinical Research Plenary Speaker**

Powel Brown, M.D., Ph.D., MD Anderson Cancer Center

*Novel cancer prevention strategies in the molecular era*

**Session V**

**Cancer Prevention Clinical Trials**

*Co-Chairs: Peter Allen, M.D. and Eva Szabo, M.D.*

3:30-4:00 PM      **Overview of the Cancer Prevention Clinical Trials Network (CP-CTNet)**

Eva Szabo, M.D., Division of Cancer Prevention, NCI

- 4:00-4:30 PM      Speaker 1: Peter Allen, M.D., Duke University  
*Intraductal Papillary Mucinous neoplasms of the pancreas: An opportunity to prevent pancreatic cancer?*
- 4:30-5:00 PM      Speaker 2, Eduardo Vilar-Sanchez, M.D., Ph.D., MD Anderson Cancer Center  
*Cancer immune-interception for Lynch Syndrome*
- 5:00-5:30 PM      Speaker 3: Seema Khan, M.D., Northwestern University  
*Local transdermal drug delivery to the breast for cancer prevention*
- 5:30-6:00 PM      Speaker 4: Andrew Chan, M.D., M.P.H., Massachusetts General Hospital  
*Novel strategies for aspirin prevention of cancer*
- 6:00-6:15 PM      **Closing Remarks, Future Plans for Prevention Meetings**  
Altaf Mohammed, Ph.D., Division of Cancer Prevention, NCI  
Mark Miller, Ph.D., Division of Cancer Prevention, NCI